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Here, we present a unifying hypothesis about how messenger RNAs, transcribed pseudogenes,
and long noncoding RNAs ‘‘talk’’ to each other using microRNA response elements (MREs) as
letters of a new language. We propose that this ‘‘competing endogenous RNA’’ (ceRNA) activity
forms a large-scale regulatory network across the transcriptome, greatly expanding the functional
genetic information in the human genome and playing important roles in pathological conditions,
such as cancer.The Noncoding Revolution
Lower organisms such as Caenorhabditis
elegans have a comparable number of
protein-coding genes as humans (Balti-
more, 2001). However, the human
genome is 30 times larger than that of
C. elegans, suggesting that the noncod-
ing portion of the genome is of crucial
importance in dictating the greater
complexity of higher eukaryotes (Costa,
2008; Mattick, 2009). Indeed, a significant
proportion of the mammalian transcrip-
tome does not correspond to annotated
exons of protein-coding genes (Kapranov
et al., 2007), implying that the fraction of
the mammalian genome ‘‘carrying infor-
mation’’ is significantly larger than previ-
ously expected. Remarkably, systematic
analyses of the cancer genome and tran-
scriptome have identified profound alter-
ations in noncoding genes (Beroukhim
et al., 2010; Futreal et al., 2004; Stratton
et al., 2009). Rearrangements, such as
deletion, amplification, inversion, and
chromosomal translocation, are observed
to alter noncoding genes, as they do to
coding genes.
Although recent studies have begun
associating a subset of long noncoding
RNAs (lncRNAs) with specific regulatory
mechanisms, less is known about non-
coding transcripts on a genome-wide
scale (Nagano and Fraser, 2011). More-
over, little is still known of the potential
noncoding functions of coding genes.
Recent theoretical and experimental
studies have suggested that, in particularcases (Seitz, 2009; Poliseno et al., 2010),
RNAs influence each others’ levels by
competing for a limited pool of micro-
RNAs. Here, we describe a unifying
hypothesis that attributes this new and
potentially predictable function to the
coding and noncoding transcriptome.
We outline this ‘‘competitive endogenous
RNA’’ (ceRNA) hypothesis, including its
logic, and then discuss recent experi-
mental evidence for it and the conse-
quences of altering its homeostasis.
Overall, we hypothesize that all types of
RNA transcripts communicate through
a new ‘‘language’’ mediated by micro-
RNA-binding sites (‘‘microRNA response
elements,’’ or ‘‘MREs’’) and that recent
advances in experimental techniques are
finally allowing us to hear and translate
this language.
The ceRNA Protagonists
MicroRNAs
Approximately 22 nucleotides in length,
microRNAs bind to sequences with
partial complementarity on target RNA
transcripts, called microRNA response
elements (MREs), usually resulting in the
repression of target gene expression
(Bartel, 2009; Thomas et al., 2010).
MicroRNAs can function in a combinato-
rial manner if an mRNA transcript harbors
numerous MREs. Furthermore, each mi-
croRNA may repress up to hundreds of
transcripts, and thus, it is estimated that
microRNAs regulate a large proportion
of the transcriptome (Friedman et al.,Cell 12009; Thomas et al., 2010). In fact,
microRNAs have been implicated in
numerous diseases (http://cmbi.bjmu.
edu.cn/hmdd), including cancer (Calin
et al., 2002; Lu et al., 2008).
The Transcriptome
The protein coding genes. Approximately
20,000 protein-coding genes have been
identified in the human genome, many of
which are densely covered in MREs
(Baltimore, 2001; Friedman et al., 2009).
Our increasing capacity to identify MREs
on coding gene transcripts allows us to
predict the extent of microRNA-depen-
dent regulation. We believe that this
predictability, coupled with appropriate
validation steps, will be critical in vali-
dating the ceRNA hypothesis.
Pseudogenes. Pseudogenes are
genomic loci that resemble known genes
but are defined as ‘‘nonfunctional,’’
‘‘junk,’’ or ‘‘evolutionary relics’’ because,
except for a fewcases, theydonot encode
functional proteins; their translation is in-
terrupted by premature stop codons,
frameshift mutations, insertions, or dele-
tions (D’Errico et al., 2004). Sequencing
efforts have revealed 19,000 pseudo-
genes in humans, many of which are tran-
scribedandareoftenwell conserved, sug-
gesting that selective pressure tomaintain
pseudogenes exists (Pink et al., 2011).
Despite lacking canonical promoters,
processed pseudogenes (i.e., ones
without introns) can use proximal regula-
tory elements for transcription (Birney
et al., 2007). Indeed, transcription of46, August 5, 2011 ª2011 Elsevier Inc. 353
Figure 1. The Basis of the ceRNA Language
How mRNAs affect microRNAs is less well characterized than how microRNAs affect mRNAs.
(A) The relationship betweenmRNAs andmicroRNAs could be reciprocal (Seitz, 2009), causing the level of
one mRNA to influence the level and activity of another mRNA.
(B) Thus, RNAmolecules could communicate with each other through microRNA andmicroRNA response
sequences (MREs). The greater the number of sharedMREs, the greater the level of ‘‘communication’’ and
thus coregulation.
(C) The 30 UTRs of RNA molecules contain MREs, which can function in cis to regulate the RNA molecule
itself but also possibly in trans to regulate levels of microRNAs and consequently other RNAs.pseudogenes displays tissue specificity
and can be activated or silenced in
specific pathological conditions, such as
cancer (Pink et al., 2011). Importantly,
the high-sequence conservation between
gene and associated pseudogenes
implies that the same microRNAs can
target them (Poliseno et al., 2010).
Long noncoding RNAs. Long noncod-
ing RNAs (lncRNAs) are typically 300 to
thousands of nucleotides in length. The
number of reported lncRNAs is expand-
ing, and of these, a subset has been
linked to epigenetic mechanisms,
including X-inactive specific transcript
(XIST), which is implicated in X chromo-
some inactivation (Brown et al., 1992),
and the recently identified large intergenic
noncoding (linc)-RNAs (Gong and
Maquat, 2011; Guttman et al., 2009;
Huarte et al., 2010; Khalil et al., 2009).
Importantly, microRNAs also regulate
lncRNAs, as shown in a recent global
analysis of Argonaute (Ago)-bound tran-
scripts through the HITS-CLIP technique
(Chi et al., 2009; Licatalosi et al., 2008).354 Cell 146, August 5, 2011 ª2011 ElsevierThe ceRNA Hypothesis
RNA Transcripts Communicate
through the ceRNA Language
MicroRNAs are negative regulators of
gene expression, decreasing the stability
of target RNAs or limiting their translation
(Fabian et al., 2010). Accordingly, micro-
RNAs are commonly viewed as active
regulatory elements, whereas the target
mRNAs are viewed as passive targets of
repression (Figure 1A, left).
By contrast, in 2009, Seitz hypothe-
sized that computationally identified
microRNA-binding sites can titrate
miRNAs and thereby regulate microRNA
availability (Seitz, 2009). Seitz focused
largely on low-affinity ‘‘pseudotargets,’’
while we theorize that ‘‘legitimate targets’’
are the key regulators of miRNAs, making
them easy to predict computationally.
Indeed, we recently demonstrated exper-
imentally that pseudogenes, due to their
high-sequence homology, can act as
legitimate bona fide microRNA competi-
tors, thereby actively competing with their
ancestral protein-coding genes for theInc.same pool of microRNAs through sets of
conserved MREs (Poliseno et al., 2010).
The consequence of competition for
microRNAs is observed as a decrease in
microRNA detection and thus an im-
pairment of microRNA activity (Cazalla
et al., 2010; Lee et al., 2010; Wang et al.,
2010).
Thus, we hypothesize that, in addition
to the conventional microRNA/RNA
function, a reversed RNA/microRNA
logic exists (Figure 1A, right), in which
bona fide coding and noncoding RNA
targets can crosstalk through their ability
to compete for microRNA binding. On
the basis of this hypothesis, MREs can
be viewed as the letters of an ‘‘RNA
language’’ by which transcripts can
actively communicate to each other to
regulate their respective expression levels
(Figure 1B). We hypothesize that RNAs
that share multiple MREs will crosstalk
effectively. Importantly, we predict that
this ‘‘RNA language’’ can be used to func-
tionalize the entire mRNA dimension
through the identification of crosstalking
ceRNAs, as well as ceRNA networks.
In addition to attributing a new, global
function for all of the noncoding RNAs,
the ceRNA hypothesis challenges the
notion that a protein-coding gene must
be translated into a protein to exert
function. We propose that mRNAs may
also possess an additional and predict-
able function through their ability to
regulate other mRNAs. Moreover, the
noncoding function of mRNA may be
consistent with the coding function, but
the two functions could also be inco-
herent or even opposite in effect, thereby
creating built-in regulatory loops, func-
tional complexity, and diversification in
both physiological and pathological
conditions.
Furthermore, the ceRNA hypothesis
may explain the regulatory function of
30UTRs (Rastinejad and Blau, 1993; Rasti-
nejad et al., 1993). Besides acting as cis
regulatory elements that alter the stability
of their own transcripts, 30UTRs may also
act in trans to modulate gene expression
through microRNA binding (Figure 1C).
This is particularly relevant given the
recent identification of 30UTRs expressed
separately from the associated protein-
coding sequences to which they are
normally linked (Mercer et al., 2011). In
addition, we are proposing that all types
of RNAs may compete with each other for
microRNAs, generating large-scale trans-
regulatory crosstalk across the transcrip-
tome as a whole.
Logic and Regulation of the ceRNA
Network
The ceRNA hypothesis relies on a knowl-
edge of the precise number and location
of MREs—‘‘the letters’’ of the RNA code.
Although several target prediction algo-
rithms are successful in identifying some
microRNA targets, they commonly fail
to predict some important microRNA
targets, mainly because the rules of
targeting are still not understood (Bartel,
2009; Thomas et al., 2010). We expect
that better target prediction algorithms
and innovative biochemical techniques
will contribute significantly to the defini-
tion of the ceRNA language. For example,
the high-throughput sequencing of
RNAs isolated by crosslinking immuno-
precipitation, or HITS-CLIP, allows the
identification of MREs associated with
the RNA-induced silencing complex
(RISC) (Thomas et al., 2010).
What cellular conditions must exist for
ceRNA network to occur? First, the rela-
tive concentration of the ceRNAs and
their microRNAs is clearly important.
Changes in the ceRNA expression levels
need to be large enough to either over-
come or relieve the microRNA repression
on competing ceRNAs. This is exempli-
fied by RNA transcripts ‘‘switched’’ on or
off at the transcriptional level in different
developmental stages or physiological/
pathological conditions. Similarly, the
expression levels of the sequestered
microRNAs could be neither absent nor
grossly overexpressed because either
condition will abolish competition.
Second, the effectiveness of a ceRNA
would depend on the number of micro-
RNAs that it can ‘‘sponge.’’ This, in turn,
would depend on the ceRNA’s accessi-
bility to microRNA molecules, which is
influenced by its subcellular localization
and its interaction with RNA-binding
proteins. The specific tissue, develop-
mental, or pathological context in which
the ceRNA is expressed would also
impact its overall influence because not
all microRNAs are present everywhere
and at all times (Venables et al., 2009).
Although a ceRNA network could be built
around a single microRNA, we hypothe-
size that themost robust ceRNA networkswould contain transcripts that share
multipleMREs targeted bymultiplemicro-
RNAs. Thus, overall, ceRNA networks
would also depend on the identity,
concentration, and subcellular distribu-
tion of the RNA and themicroRNA species
that are present in a given cell type at
a given moment.
Third, not all of the MREs on ceRNAs
are equal. Although two MREs may be
predicted to bind the same microRNA,
their specific nucleotide composition
may be partially different, and the effec-
tiveness of each MRE to bind a microRNA
is critical for overall ceRNA function.
Similarly, microRNAs are predicted to
target tens to hundreds of RNAs, but
they do not exert the same degree of
repression on all of them; the primary
targets are usually few, whereas the rest
are finely tuned (Bartel and Chen, 2004;
Seitz, 2009). It is conceivable that, if
a given microRNA is sequestered by
a ceRNA, the primary targets of that mi-
croRNA would be preferentially affected.
Experimental Evidence Supporting
the ceRNA Hypothesis
More recently, our work demonstrated
experimentally that, indeed, a noncoding
pseudogene can bind to and compete
for the same collection of microRNAs as
its ancestral gene (Poliseno et al., 2010).
Specifically, we found that many MREs
in the tumor suppressor gene PTEN are
conserved in its related pseudogene
PTENP1, and overexpression of the
PTENP1 30UTR increased levels of PTEN
and growth inhibition in a DICER-depen-
dent manner. Interestingly, copy number
losses at the PTENP1 locus in sporadic
colon cancer suggest that PTENP1 could
be considered a tumor suppressor gene
(Poliseno et al., 2010).
We and other laboratories have
extended this analysis to other gene-
pseudogene partners (e.g., KRAS and its
pseudogene KRAS1P) and protein-
coding mRNAs (e.g., PTEN 30UTR [Poli-
seno et al., 2010], versican 30UTR [Lee
et al., 2009; 2010), and CD44 30UTR
[Jeyapalan et al., 2010]). Overall, these
findings suggest that 30UTRs from both
pseudogenes and coding genes may
possess powerful biological activity
through their ability to act as endogenous
decoys for microRNAs.
Approximately three years before the
identification of these endogenousCell 1decoys, numerous studies found that
exogenously expressed ‘‘microRNA
sponges’’ were able to inhibit microRNA
function specifically and effectively (Ebert
et al., 2007; Brown et al., 2007; Gentner
et al., 2009). MicroRNA sponges are artifi-
cial transcripts that contain multiple
copies of a single MRE in tandem. They
are often cloned into viral vectors so that
they can be expressed at high levels
(Ebert and Sharp, 2010). The applications
for sponging constructs are exciting and
perhaps the future of RNA-based thera-
peutic modalities (Brown et al., 2007;
Gentner et al., 2009). Analogously, we
propose that ceRNAs are ‘‘endogenous
sponges’’ that are able to impact the
distribution of microRNA molecules on
all of their targets. Unlike artificial
sponges, ceRNAs contain MREs for
a combination of different microRNAs;
thus, they can impact the multiple targets
of multiple microRNAs.
In addition to pseudogenes, other
examples of ceRNA have been reported
recently. Franco-Zorrilla and colleagues
demonstrated that the noncoding RNA
IPS1 in Arabidopsis thaliana sequesters
miR-399 by mimicking its target site,
a phenomenon called ‘‘target mimicry’’
(Franco-Zorrilla et al., 2007). Analogously,
a noncoding RNA in herpesvirus saimiri
RNA has been shown to bind to and cause
the degradation of human miR-27 to
possibly produce a permissive cellular
environment for viral infection and trans-
formation (Cazalla et al., 2010). Further-
more, highly upregulated in liver cancer
(HULC) lncRNA sequesters endogenous
miR-372 to modulate its own transcrip-
tional upregulation in HCC (Wang et al.,
2010). Notably, all of the endogenous
sponges reported thus far do not encode
for proteins.
Although our hypothesis applies to both
protein-coding and noncoding RNAs, we
speculate that noncoding ceRNAs may
be highly effective inhibitors precisely
because they are devoted to microRNA
binding, without any interference from
active translation (Gu et al., 2009). Further
development and widespread use of
HITS-CLIP and other related techniques
will ultimately reveal the full extent of
pseudogene and lncRNA regulation by
microRNAs and, consequently, their
respective impact and positioning within
ceRNA networks.46, August 5, 2011 ª2011 Elsevier Inc. 355
Figure 2. MicroRNA Effectiveness Is Influenced by the Cellular Concentration of Its MREs
Multiple RNA transcripts can contain MREs for the same microRNA. As proposed by the ceRNA
hypothesis, overexpression of RNA Y (e.g., by transcriptional activation) increases cellular concentrations
of particular MREs and can result in the derepression of other transcripts (e.g., RNA X) that contain the
same MREs. Vice versa, downregulation of RNA Y would lead to decreased levels of particular MREs,
hyperrepression of RNA X, and, consequently, decreased expression.The ceRNA hypothesis is strongly sup-
ported by the fact that a single micro-
RNA’s effectiveness is influenced by the
concentration of its target mRNAs (Arvey
et al., 2010). MicroRNAs that have a larger
repertoire of target genes may downregu-
late each individual target gene to a lesser
extent thanmicroRNAswith fewer targets.
By the same token, when a givenmRNA is
upregulated, the repression conferred by
its targeting microRNAs would be diluted
because the total number of MREs
exceeds that of the microRNAs them-
selves (Figure 2). Thus, altering the
expression levels of an individual ceRNA
would have repercussions on other ceR-
NAs with which it shares MREs.
ceRNAs in the Etiology of Cancer
In principle, almost any RNA molecule
that possesses at least one MRE acces-
sible to microRNA binding could act as356 Cell 146, August 5, 2011 ª2011 Elseviera ceRNA. Therefore, characterizing the
ceRNA networks requires the accurate
identification of MREs within RNA mole-
cules. Indeed, we speculate that this
type of analysis could uncover molecular
interactions and gene regulatory net-
works that have been missed by proteo-
mic and conventional genomic methods.
In this framework, aberrant expression of
coding and noncoding genes should be
systematically studied in the context of
human disease.
Pseudogenesare a compelling example
of ceRNA because they likely posses
many (if not all) of the same MREs that
are harbored on their ancestral genes and
thus can act as ‘‘perfect sponges.’’ How-
ever, the ability of pseudogenes to regu-
late the biology of a cell may go beyond
the modulation of the levels of their
ancestral genes. For instance, PTENP1 is
biologically active even in a PTEN nullInc.context, as it alters the microRNA net-
work normally regulating PTEN (Poliseno
et al., 2010). Moreover, genes such as
OCT4,NPM1, andmany ribosomal protein
genes often have numerous differentially
regulated pseudogenes (Balasubrama-
nian et al., 2009), indicating that gene-
pseudogenenetworks canbecomeexten-
sive and intricately dynamic.
In the context of cancer, a straightfor-
ward implication of our hypothesis is
that pseudogenes and lncRNAs should
now be systematically studied as poten-
tial tumor suppressors and oncogenes
through their ceRNA function. Accord-
ingly, the notion of endogenous lncRNA
sponges was recently linked to the
progression of liver cancer. It was re-
ported that the lncRNA HULC is one of
themost upregulated of all genes in hepa-
tocellular carcinoma (Panzitt et al., 2007).
Wang and colleagues identified that
CREB (cAMP response element binding
protein) is involved in the upregulation of
HULC (Wang et al., 2010). They also
demonstrated that HULC RNA inhibits
miR-372 activity through a ceRNA func-
tion. This, in turn, leads to derepression
of one of its target genes, PRKACB, which
can then induce the phosphorylation and
activation of CREB. Overall, HULC
lncRNA is part of a self-amplifying autore-
gulatory loop in which it sponges miR-372
to activate CREB and in turn upregulates
its own levels.
Gross genomic losses and amplifica-
tions commonly observed in cancer could
have potentially dramatic consequences
for the ceRNAs contained in those
regions. Moreover, under the ceRNA
hypothesis, gene loss events should be
clearly distinguished from point mutations
that abolish protein function but retain full
ceRNA function.
If the ceRNA hypothesis proves correct,
then one would need to consider the
repercussions of knocking out and over-
expressing ceRNAs when modeling
diseases in mice. For instance, when
generating knockout mice, one must
consider whether only the transcript or
also the protein expression is disrupted.
Many experimental techniques normally
neglect UTRs and limit functional studies
to gene coding regions. For example,
when generating transgenic mice, it has
been standard to only overexpress
coding sequences, but not UTRs.
Figure 3. Potential Pathological Alterations of Cellular ceRNA
Many types of genetic events can alter the abundance or sequence of
a particular transcript. As proposed by the ceRNA hypothesis, these events
could induce ‘‘coding-independent’’ effects by altering the levels of micro-
RNAs that are available for silencing particular transcripts.However, binding sites for mi-
croRNAs could occur in
30UTRs, 50UTRs, and coding
regions (Tay et al., 2008), sug-
gesting that the entire tran-
script may possess an
inherent trans regulatory func-
tion. Thus, by limiting their
focus or scope to coding
region, many conventional
tools and techniques may
have been neglecting the full
function of the gene.
Chromosomal translocation
events and recurrent ‘‘read-
through’’ transcripts are com-
mon in cancers. For example,
the t(15;17) translocation that
generates PML-RARa and
RARa-PML fusion transcripts
is often seen in acute pro-
myelocytic leukemia, whereas
the ‘‘readthrough’’ transcript
CDK2-RAB5B is common in
melanoma (Berger et al.,2010; Scaglioni and Pandolfi, 2007). Such
events couldbeconsidered ‘‘UTRswaps,’’
leading to perturbed MRE levels due to
misplacement and consequent altered
expression of UTRs (Figure 3). ceRNA
perturbation could also occur as a con-
sequence of somatic genomic rearrange-
ments affecting noncoding regions, which
are emerging as hitherto unappreciated
events in many cancers (Stephens et al.,
2009).
Aberrant alternative splicing events
could also introduce new RNA sequences
and potentially new MREs into the cell.
Because splicing can be perturbed in
disease and cancer (Venables et al.,
2009), the associated perturbation of the
ceRNA network may also contribute to
pathologies. Similarly, the shortening of
30UTRs as observed in human cancer cells
(Mayr and Bartel, 2009) would not only
impact microRNA-dependent mRNA
regulation but, vice versa, could also alter
the capacity of a givenmRNA transcript to
‘‘sponge’’ or titrate away microRNAs.
All of these described events have a
singlecommonality: they representpertur-
bations in the expression levels of a given
transcript (and consequentially MREs),
irrespective of whether or not the tran-
script is translated into a protein. Thus, it
will be interesting to determine whether
elevated or depressed levels of a giventranscript could exert oncogenic activities
by altering competition for miRNAs.
Conclusions
In conclusion, we hypothesize that cross-
talk between RNAs, both coding and
noncoding, through MREs, forms large-
scale regulatory networks across the
transcriptome. This ceRNA activity could
offer answers to evolutionary questions,
as it may, in part, explain the correlation
of genome size and organism complexity.
Moreover, perturbations of ceRNA and
ceRNA networks could have conse-
quences for diseases, but on the flip
side, it may explain disease processes
and present opportunities for new thera-
pies. Although the understanding of this
field and its consequences are in their
infancy,webelieve that experimental tools
are now poised to fully identify microRNA-
binding sites and catalogue the basic
lexicon of the ceRNA ‘‘language.’’ We
envision that the ceRNA language will
allow us to predict andmanipulate regula-
tory networks working through microRNA
competition. Future challenges will then
be to understand why such regulatory
networks exist, how they may have
evolved, and what the consequences are
when they are perturbed. Only then will
we be able to fully decipher the ‘‘Rosetta
Stone’’ of this hidden RNA language.Cell 146, August 5ACKNOWLEDGMENTS
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